Briacell Therapeutics Corp. Common Shares (BCTX) Dividend History

Briacell Therapeutics Corp. is a biotechnology company focused on developing personalized cell therapies for cancer treatment. The company leverages its proprietary platform to design and manufacture immune cell therapies aimed at improving outcomes for patients with various cancers.

3rd Floor, Bellevue Centre, 235-15th Str, West Vancouver, A1, V7T 2X1
Phone: (604) 921-1810
Website: https://www.briacell.com

Dividend History

Briacell Therapeutics Corp. Common Shares currently does not pay dividends

Company News

New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty

The article discusses the rise in cancer incidence and the need for better treatments, as well as the potential impact of budget reductions and new tariffs on innovation. Several oncology companies, including Oncolytics Biotech, Sutro Biopharma, BriaCell Therapeutics, and Tempus AI, have reported notable updates in 2025.

Benzinga

Featured Companies: ONCY STRO TEM
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

BriaCell Therapeutics Corp. announced the pricing of a $13.8 million public offering, with each unit consisting of one common share (or pre-funded warrant) and one warrant. The company plans to use the proceeds for working capital, general corporate purposes, and advancing its business objectives.

GlobeNewswire Inc.
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

BriaCell Therapeutics, a clinical-stage biotechnology company, will present three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The posters will cover topics related to their cancer immunotherapy pipeline, including Bria-ABC1, Bria-IMT, and Bria-OTS+.

GlobeNewswire Inc.
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer

The Data Safety Monitoring Board (DSMB) has recommended the continuation of BriaCell's pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer, as no safety concerns were identified. This is a positive development for the company's groundbreaking immunotherapy treatment.

GlobeNewswire Inc.
BriaCell Therapeutics Announces Closing of Public Offering

BriaCell Therapeutics announced the closing of its public offering, raising $3.05 million. The company plans to use the proceeds for working capital, general corporate purposes, and advancing its business objectives.

Benzinga

Dividend data last updated 06/07/2025 01:06:55 UTC